The pandemic continues to pose near-term risks as new variants of the virus and rising infection rates prompt governments to extend restrictions. However, vaccines and continued monetary and fiscal-policy stimulus bode well for global growth and will be supportive of Japanese equities. Several themes present themselves. Clean energy and environmental-efficiency are areas where Japan has some very competitive companies. Covid-19 has also accelerated trends in e-commerce and digitalisation. As profits recover, companies will prioritise those areas.
Above all, Japan continues to offer a wealth of under-researched mid- and small-cap growth companies, where we typically find better business models and returns on equity (a key gauge of profitability), and management has more incentives in terms of shareholder returns. Active managers like myself, based here in Japan, get the opportunity not only to invest in established global leaders but also to unearth less well-known companies, where lower levels of coverage by analysts can often yield great mispriced opportunities.
NOF: delivering drugs and profits
NOF (Tokyo: 4403) is a diversified chemicals company with strong positions in many niche markets, resulting in stable growth and high profitability. Its core businesses include surfactants (inputs for toiletries and cosmetics) and drug-delivery system (DDS) products, which ensure that a drug’s active ingredient is delivered and absorbed safely in the right part of the body.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
DDS is a crucial component in mRNA technology (a new form of cancer treatment and also the basis of the Pfizer and Moderna vaccines) and other new treatments, and growth in this field benefits NOF as the market leader. While the stock is often overlooked, this is slowly changing as we successfully engage with the company’s new president to improve the group’s environmental, social and governance and disclosure policies.
Mitsui High-tec: motor-core expert powers ahead
Mitsui High-tec (Tokyo: 6966) comprises almost 70% of the global motor-core market, an essential component of power-train motors in electric and hybrid vehicles. The company’s strength lies in its ultra-precision machining and die technology, which is used to create high-quality motor cores and machine tools. Mitsui High-tec is a dominant supplier and it aims to expand its motor-core production capacity sixfold through 2030, a clear sign of confidence in its order backlog. Yet with a market capitalisation of only £1bn and little coverage, this is a name with significant upside potential.
Coconala: an online freelancers’ market
Coconala (Tokyo: 4176) is a unique online freelancing platform that enables users to trade knowledge, skills and experience. We first invested in the company in 2019, when it was unlisted, recognising it as a beneficiary of the many structural changes occurring in Japan’s labour market; we were attracted by its high and sustainable growth rates as well as the high operating leverage of its business.
Coconala recently had a strong debut on the Tokyo Stock Exchange and the value of the our holding increased more than threefold. The success of this investment highlights the benefits of our research on the ground and efforts to find the most attractive opportunities in corporate Japan.
-
Santander launches new freebie for certain savings customers - are you eligible?Santander is offering a free four-year railcard to some customers from today. We explain who will qualify for the incentive
-
Lloyds axes foreign currency fees for Club Lloyds customersClub Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
-
The star small and mid-cap stocks income investors have overlookedOpinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Chemring Group: an explosive investment opportunity in defenceEuropean states are raising their military spending, and Chemring Group looks well placed to profit
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
